{"id":4125,"date":"2026-11-04T15:00:00","date_gmt":"2026-11-04T19:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4125"},"modified":"2026-11-07T16:07:49","modified_gmt":"2026-11-07T20:07:49","slug":"il1rap-antibody-shows-early-responses-in-mds-and-aml-cohorts","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4125","title":{"rendered":"IL1RAP Antibody Shows Early Responses in MDS and AML Cohorts"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"768\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Cantargia_Therapeutic_Indications-768x768.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4145\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Cantargia_Therapeutic_Indications-768x768.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Cantargia_Therapeutic_Indications-300x300.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Cantargia_Therapeutic_Indications-1024x1024.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Cantargia_Therapeutic_Indications-150x150.png 150w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Cantargia_Therapeutic_Indications.png 1254w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>Cantargia<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>Phase 1b\/2a data disclosure (ASH abstract)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>Monoclonal antibody<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>Nadunolimab (CAN04)<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>IL1RAP<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Higher-risk MDS; relapsed\/refractory AML<\/p>\n<h4>Summary<\/h4>\n<p>Previously missed November 4 issuer disclosure of ASH-abstract data: in an investigator-initiated Phase 1b\/2a trial of nadunolimab, seven of ten evaluable higher-risk MDS patients responded on azacitidine combination, and three of nine adverse-risk relapsed\/refractory AML patients responded on azacitidine plus venetoclax. Small, nonrandomized cohorts preclude a treatment-effect claim.<\/p>\n<p>At a June 30 cutoff, 22 were enrolled and 19 completed at least one cycle and were evaluable. MDS responses comprised two CR, two CRh and three CRL under IWG 2023; AML comprised one CR, one CRh and one MLFS under ELN 2017. Company attribution classified one grade 3\/4 infusion reaction as likely antibody-related. Phase 2a expansion continues; December ASH follow-up is future data.<\/p>\n<h4>Deep Analysis<\/h4>\n<p><strong>Interpretation A:<\/strong> IL1RAP blockade and ADCC may add biological activity in genetically adverse myeloid disease. Responses in TP53 and other adverse-marker cohorts support further testing. Counterargument: azacitidine and venetoclax can themselves produce responses, and there is no control arm.<\/p>\n<p><strong>Interpretation B:<\/strong> the result may mainly reflect backbone therapy and patient selection. Small denominators support this, though durable responses in refractory subgroups would challenge it. MRD, response duration, transplant censoring, infections, cytopenias and a comparative study are decisive.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>Cantargia develops nadunolimab (CAN04), an anti-IL1RAP antibody intended to block IL-1 signaling and recruit antibody-dependent cellular cytotoxicity. Higher-risk MDS and adverse-risk AML are marrow malignancies with high relapse and mortality.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>These are actual abstracted results, not merely a conference notice.<\/li>\n<li>Efficacy denominators are evaluable patients, not all 22 enrolled.<\/li>\n<li>No survival difference or IL1RAP predictive biomarker was demonstrated.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>A worthwhile hematology hypothesis with early activity; causal attribution to the antibody remains unresolved.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 4 of 5. Signal Direction: cautiously positive for observed activity; uncertain for incremental benefit. Confidence in Facts: moderate-high for issuer data. Confidence in Interpretation: low.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Previously missed November 4 issuer disclosure of ASH-abstract data: in an investigator-initiated Phase 1b\/2a trial of nadunolimab, seven of ten evaluable higher-risk MDS patients responded on azacitidine combination, and three of nine adverse-risk relapsed\/refractory&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4145,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[1396,1370,1397],"class_list":["post-4125","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-cantargia","tag-myelodysplastic-syndromes","tag-nadunolimab"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4125","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4125"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4125\/revisions"}],"predecessor-version":[{"id":4147,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4125\/revisions\/4147"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4145"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4125"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4125"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4125"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}